Optical imaging developer VisEn Medical has expanded its FMT 2500 quantitative tomography platform to access four channels of quantitative fluorescent imaging.
The new channels -- 635 nm, 670 nm, 745 nm, and 790 nm -- are designed to provide greater flexibility in imaging and multiplexing of VisEn's fluorescent imaging agents in multiple disease pathways in vivo, according to the Bedford, MA-based company. The four-channel offering will be available in the summer of 2009 as an upgrade to existing FMT 2500 systems or as an added feature on new units.
The firm has also launched its line of FMT multimodality adapters, which allow researchers to combine FMT readouts with imaging results from microCT, PET, MR, and SPECT platforms.
In other VisEn news, the company has introduced its Fluorescent Activatable Sensor Technology (FAST) imaging agent platform for in vivo imaging of disease-associated biomarkers and drug response. The first agent, MMPSense 750 FAST, was described Monday in a scientific poster at the annual scientific sessions of the American Association for Cancer Research (AACR) in Denver, VisEn said.
The poster described the near-infrared imaging agent's ability to measure tumor matrix metalloproteinase (MMP) activity in vivo and to monitor treatment efficacy, VisEn said.
Related Reading
VisEn adds to management team, January 8, 2009
VisEn debuts IntegriSense, August 19, 2008
VisEn nets $3.5M in financing, July 22, 2008
VisEn secures financing, October 26, 2007
VisEn brings molecular imaging probe to market, June 7, 2007
Copyright © 2009 AuntMinnie.com
